Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome -Multi-center, Open-label, historical Control Comparative Study

Trial Profile

Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome -Multi-center, Open-label, historical Control Comparative Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Viral infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 26 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top